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Prevalence of Polypharmacy and Association to Pharmacotherapy 
Complexity in Older HIV-Positive Patients. The Sevihlla Study                                
Background: Increased life expectancy of older HIV-positive pa-
tients has been associated to a parallel increase in age-related 
comorbidities. 
Objectives: To ascertain the prevalence of polypharmacy and 
its association to pharmacotherapy complexity, as measured by 
the Medication Regimen Complexity Index, in older HIV-positive 
patients; to calculate the median value of pharmacotherapy com-
plexity; to identify polypharmacy and multimorbidity patterns; and 
to address adherence to antiretroviral and concomitant drugs.
Methods: A cross-sectional, observational study was conducted 
in patients over 50 years of age receiving active antiretroviral 
drugs during 2014 at outpatient pharmacy services of a tertiary 
hospital in Spain. Data collected from the electronic medical re-
cord included demographic, clinical and comorbidity related end-
points. 
The primary endpoint was the proportion of patients with poly-
pharmacy and major polypharmacy. Polypharmacy was defined 
as treatment with six or more drugs (including antiretroviral). 
Major polypharmacy (more than 11 drugs) was also considered.
Patients was categorized according to their polypharmacy pat-
tern. Three patterns were applied based on age of participants: 
cardiovascular, depression-anxiety, and chronic obstructive pul-
monary (COPD) disease patterns. A patient was classified into 
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a pattern when at least three drugs of the treatment were in the same pattern. 
Antiretroviral treatment adherence was measured using the SMAQ questionnaire and hospital 
dispensing records. Adherence to concomitant medication was measured using the Morisky-Green 
questionnaire and electronic pharmacy dispensing records.  
Pharmacotherapy complexity index, as assessed by MRCI, was also considered. Patients were 
classified as low MRCI (less than 14 points) or high MRCI (more than 14 points).  
Results: The study sample consisted of 223 patients (86.5% men), with a median age of 53.0 
years. More than 80.0% of the patients were viro-inmunological controlled. Prevalence of 
polypharmacy was 56.1%. The median value of pharmacotherapy complexity was 11.0. The main 
contribution to this value was from the concomitant medication.  
The polypharmacy pattern mainly calculated was cardiovascular (60.0%) and the multimorbidity 
pattern was cardiometabolic (73.8%). 
Presence of polypharmacy was associated to greater pharmacotherapy complexity (p<0,001). 
Adequate adherence to the antiretroviral and to concomitant medication was found in 83.6% and 
37.9% of patients respectively. 
Conclusions: More than a half of the older HIV-positive patients received six or more different 
drugs with a significant pharmacotherapy complexity showing adequate adherence to antiretroviral 
but not to concomitant drugs. Cardiovascular conditions were most common in terms of 
prescriptions and comorbidities. 







Worldwide mortality related to the acquired 
immunodeficiency syndrome (AIDS) of people 
infected by the human immunodeficiency virus 
(HIV) has decreased over the years, largely as 
the result of introduction of highly active 
antiretroviral therapy (ART). Thus, HIV-infected 
individuals live longer. It is estimated that by 
2030 nearly three-quarters of people living with 
HIV will be 50 years or older. Age-related 
conditions such as cardiovascular disease, 
kidney disease, and non-AIDS-defining cancers 
are likely to continue to increase among HIV-
infected patients as their median age also 
increases 1,2. This high prevalence of 
comorbidities has only exacerbated the 
polypharmacy problem, which has recently 
become a clinical concern among providers 
caring for HIV-infected patients 3–5. 
There are different definitions of polypharmacy. 
In numerical terms, it is most commonly defined 
as at least five or more prescription drugs, 
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which is also associated to worse health 
outcomes in older patients 6. Polypharmacy 
should be considered the next challenge in 
clinical follow-up of HIV-infected patients for 
several reasons. First, HIV-positive patients are 
taking increasingly more drugs to manage 
multimorbidity 7. Second, polypharmacy has a 
major impact on traditional aspects such as 
adherence, leading to worse treatment 
outcomes 8–12. Third, the risk of clinically 
relevant drug interactions increases with 
polypharmacy, and the aging HIV population is 
at an even higher risk 13.  
Finally, another critical but less known factor is 
pharmacotherapy complexity (PC). Martin et al. 
developed a method for quantifying 
antiretroviral regimen complexity for HIV 
patients 14. This method was the first step 
toward obtaining a better understanding of the 
impact of complex ART regimens on adherence 
and clinical outcomes. Libby et al. subsequently 
developed a medication regimen complexity 
index (MRCI) to estimate complexity of all 
drugs taken by a patient (HIV and non-HIV 
drugs) 15. Although the impact of regimen 
complexity, number of drugs, and pill burden on 
medication adherence has been addressed in 
scientific literature, most studies have focused 
on use of antiretrovirals and have failed to 
consider the impact of other drugs or therapies. 
No studies addressing this issue have been 
published yet. 
Study objective 
The purpose of this study was to determine the 
prevalence of polypharmacy and its association 
to PC, as measured by MRCI, in older HIV-
positive patients. The secondary objectives 
were to calculate the median value of PC; to 
identify polypharmacy and multimorbidity 
patterns, describing the concomitant medication 
most often prescribed and assessing the PC 
index, with attention to the appearance of drugs 
(pharmaceutical form, dosage, and specific 
instructions); and to address adherence to 
antiretroviral and concomitant drugs. 
A final objective was to explore whether the 
complexity index is associated to adherence, 
based on the multimorbidity pattern. 
Ethics approval 
The study was approved by the institutional 
ethics committee of the South Seville area. 
Participants were given written information 
about the study and its objectives, and those 
who agreed to take part provided their written 
informed consent. 
MATERIALS AND METHODS 
A cross-sectional, observational study was 
conducted. Patients enrolled in the study met 
the following inclusion criteria: HIV patients over 
50 years of age on active ART drugs from 1 
January 2014 to 31 December 2014. 
Participants were given written information 
about the study and its objectives, and those 
who agreed to participate provided their written 
informed consent. 
Patients participating in another clinical trial or 
who did not sign the informed consent were 
excluded. 
Data collected from the electronic medical 
record included demographic data (sex and 
age) and HIV transmission mode; clinical 
endpoints: plasma viral load (copies/milliliter 
[mL]) and CD4+ T-cell count (cells/microliter), 
and comorbidity related endpoints (number and 
type of comorbidities, particularly liver, central 
nervous system and cardiovascular disease or 
high blood pressure). Charlson comorbidity 
index was also included 16.  
Pharmacotherapy endpoints included ART 
regimen and concomitant medications (drugs 
for acid-related disorders, psycholeptics or 
psychoanaleptics, lipid-lowering drugs and 
other drugs for cardiovascular disease or 
diabetes, among others). The PC index, as 
assessed by MRCI, was also considered. This 
validated tool includes 65 items divided into 
three subgroups: dose forms, dosing 
frequencies, and additional instructions relevant 
to drug administration. The calculated value 
was obtained through the web tool of Colorado 
Ramón Morillo-Verdugo et al., IJOAR, 2019 2:35 
IJOAR: https://escipub.com/international-journal-of-aging-research/                        4
University available at 
http://www.ucdenver.edu/academics/colleges/p
harmacy/Research/researchareas/Pages/MRC
Tool.aspx) 17 . Based on a previous study, 
patients were classified, by consensus 
definition, as low MRCI (less than 14 points) or 
high MRCI (more than14 points) 15.  
ART adherence was measured using the 
SMAQ questionnaire and hospital dispensing 
records. Adherence to concomitant medication 
was measured using the Morisky-Green 
questionnaire and electronic pharmacy 
dispensing records. 
The independent variable was polypharmacy, 
defined as treatment with six or more drugs 
(including antiretroviral therapy). Major 
polypharmacy (more than 11 drugs) and 
excessive polypharmacy (more than 21 drugs) 
were also considered. 
Polypharmacy pattern was analyzed according 
to the Calderón Larrañaga et al study 18, with a 
non-random association in drug prescription 
resulting in polypharmacy patterns. Three 
patterns were applied based on age of 
participants: cardiovascular, depression-anxiety, 
and chronic obstructive pulmonary (COPD) 
disease patterns, with a different prevalence 
between men and women. A patient was 
classified into a pattern when at least three 
drugs of the treatment were in the same 
pattern. To calculate the corresponding 
polypharmacy patterns of each patient, drugs 
were classified according to the Anatomical 
Therapeutic Chemical Classification System 
(ATC) using only the first three levels of the 
classification.  
Finally, multimorbidity patterns was analyzed 
according to the Prados-Torres et al study. 
Chronic diseases resulted in three 
multimorbidity patterns: cardiometabolic, 
depressive-psychogeriatric, and mechanical-
thyroidal 19. Patients were classified into a type 
if they had two diseases included in a 
pattern.ART drugs were obtained from a 
pharmacy-dispensing outpatient program 
(Dominion-Farmatools©). Non-ART drugs 
prescribed were provided by an electronic 
health prescription program of the Andalusian 
Public Health System. The remaining endpoints 
were obtained from laboratory tests, 
microbiology reports, and from the review of the 
medical history of each patient.  
Statistical analyses 
Quantitative variables were given as mean and 
standard deviation or as median and 
interquartile range (IQR) in case of a skewed 
distribution. Qualitative variables were given as 
percentages (%).  
To compare mean values of quantitative 
variables between groups, a Student’s t test 
was used for independent samples, or a Mann-
Whitney non-parametric U test in case of non-
normal distributions. If significant differences 
were seen, 95% confidence intervals were 
found for differences in mean (or median, if 
relevant) values. Contingency tables were 
prepared and a Chi-square test was used to 
analyze the relationship between qualitative 
variables; otherwise, the Monte Carlo 
simulation with asymptotic method and exact 
test was used. 
Pearson correlation coefficients were 
calculated, and independence tests were 
performed to analyze the association between 
total PC, ART complexity, physician-
concomitant index, and Charlson index. Data 
were analyzed using IBM SPSS Statistics 
version 22.0 software 
RESULTS 
A total of 223 patients with a median age of 
53.0 years (IQR: 52.0-57.0), 86.5% males, 
were enrolled into the study. Baseline 
demographic, clinical, and lifestyle 
characteristics of patients are shown in Table 1. 
Median comorbidities per patient were 3.0 
(IQR: 2.0-4.0) with a median Charlson index of 
2.4 (IQR: 2.0-3.2). Viral liver diseases were 
diagnosed in 67.3% of patients, cardiovascular 
diseases or HBP in 25%, and central nervous 
system diseases in 20.5% of patients. 
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Table 1. Baseline demographic, clinical, and lifestyle characteristics of patients 
Characteristics (n=223 patients)  
Demographic parameters 
Sex (male) n (%) 153 (86.5) 
Age (years) (median + IQR) 53.0 (52.0-57.0) 
HIV risk factor 
n (%) 
IDU 121 (54.3) 
Sexual 68 (30.5) 
Unknown 34 (15.2) 
Clinical parameters 
Undetectable plasma viral load (<50 copies/mL) n(%) 184 (84.4) 
CD4 levels 
n (%) 
<200 cells/µL 22 (10) 
≥200 cells/µL 198 (90) 
LIFESTYLE 
BMI (kg/m2) (median+IQR) 24.6 (22.2-27.6) 
Smoking (n= 149) n (%) 66 (44.3) 
Alcohol consumption (n=156) n (%) 42 (26.9) 
Active drug users (n= 153) n (%) 10 (6.5) 
Patients with controlled BP (n=53) n (%) 47(88.7) 
History of heart disease, HBP or diabetes mellitus 
(n=188) n (%) 
Yes 15 (8.1) 
No 87 (46.2) 
Not known 86 (45.7) 
Physical activity (n=31) n (%) 13 (41.9) 
IQR, interquartile range; IDU, injection drug users; BMI, body mass index; HBP, high blood pressure; 
 
 
Figure 1. Polypharmacy pattern. COPD: chronic obstructive pulmonary disease 
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Figure 2. Multi-morbidity pattern 
 
ART regimens consisted of two nucleoside 
reverse transcriptase inhibitors (NRTI) plus a 
non-nucleoside reverse transcriptase inhibitor 
(NNRTI) in 37.2% of patients; two NRTIs plus a 
boosted protease inhibitor in 18.8%; two NRTIs 
plus an integrase strand transfer inhibitor 
(INSTI) in 12.6%, and other combinations in 
31.4% of patients. A majority (52%) of patients 
started antiretroviral therapy before 2002, and 
14.8% had been on three or more ART 
regimens. The median number of concomitant 
drugs prescribed was 3.0 (1.0-5.0). The most 
commonly prescribed therapeutic drug classes 
included psychotropic drugs (35.9%), lipid-
lowering drugs (29.1%), cardiovascular agents 
(29.1%), drugs for gastroesophageal reflux 
disease (26.9%), and glucose-lowering drugs 
(11.7%). 
The proportion of patients with high PC was 
40.4%, with a median overall score of 11 
(IQR:7-18). 
Adequate adherence to ART and concomitant 
medication was found in 83.6% and 37.9% of 
patients respectively.  
As regards the main variables, 56.1% of 
patients had polypharmacy, major 
polypharmacy in 9.4% of cases. Of the 70 
patients who were calculated the polypharmacy 
pattern, 60.0% were cardiovascular, and of the 
126 patients with multimorbidity pattern, 73.8% 
were cardiometabolic (Figs. 1 and 2). 
Presence of polypharmacy was associated to 
higher PC values. Patients with high PC indices 
had a 50 times higher chance (p = 0.0001) of 
polypharmacy than those with low PC values. 
The PC index and the concomitant medication 
index significantly correlated with the three 
index rating sections (pharmaceutical form, 
dosage, and instructions). The ART complexity 
index was only related to dosage and 
instructions (p<0.05). 
As regards the influence of the polypharmacy 
pattern on PC, the concomitant and overall PC 
index score was different (p<0.05) in patients 
with cardiovascular pattern, polypharmacy 
pattern score for COPD and mixed, which also 
occurred in the case of the depression-anxiety 
pattern. However, no significant differences 
were found between the cardiovascular and 
depression-anxiety patterns. 
Finally, the influence of overall PC on 
adherence was analyzed depending on the 
polypharmacy and metabolic pattern presented 
by the patients. PC did not affect adherence to 
both patterns. However, among patients who 
had the COPD or the mixed multimorbidity 
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pattern, those with high complexity had a 20% 
increase in adherence. 
PC did not affect adherence to both patterns. 
However, among patients who had a COPD or 
mixed multimorbidity pattern, those with high 
PC had a 20% greater adherence level. 
DISCUSSION 
Our study shows that half the elderly HIV-
positive patients currently have polypharmacy. 
These data are consistent with those reported 
by other authors 8,13,20. 
The available literature includes different 
definitions of polypharmacy. Use of five drugs 
has been a widely accepted criterion to define 
polypharmacy, but we suggest use of six drugs 
based on the most recent recommendations 6. 
The proportion of patients on polypharmacy in 
our study was however similar to that reported 
by other studies. The number of patients with 
major polypharmacy in our study (9.4%) is 
particularly important. According to the 
literature, polypharmacy will increase in the 
coming years 10. Because of this and the 
progressive physiological deterioration of 
patients, in addition to the classical assessment 
of actual or potential drug interactions, it will 
become increasingly common and necessary to 
use other terminology about use of drugs in 
other types of chronic patients, such as 
potentially inappropriate medication or 
cholinergic risk. 
The value of PC in our study was 11.0. As 
expected, concomitant drugs represented the 
main contribution to the PC value. There are 
multiple definitions of polypharmacy. Some of 
them include use of at least one unnecessary 
medication and different thresholds for the 
number of drugs in a patient’s regimen 21–23. 
There is a clear relationship between harm and 
polypharmacy. Those who are on 5–6 drugs 
have a lower risk than those on 7–8 or 9 drugs 
24–26.In a retrospective HIV-positive cohort, 
Sutton et al. 27 analyzed a different concept, the 
pill burden, which was associated to adherence 
and risk of hospitalization. Authors concluded 
that single tablet regimens (STR) were 
associated to higher adherence rates and lower 
hospitalization risks. A recent retrospective 
study found an association between 
polypharmacy, and a lower probability of using 
STR 28. Currently available STRs may be 
limited in this aging population by complex 
drug–drug and drug–disease interactions, and 
the desire to make treatment regimens more 
flexible. 
Our results are similar to those of Zhou et al 29, 
who showed that older age, comorbidity, and 
longer duration of HIV infection were 
associated to high pill burden. However, the 
study included HIV-infected patients given care 
at an outpatient clinic, but not all of them were 
over 50 years of age. 
Designing ART regimens that do not interact 
with other chronic medications or exacerbate 
comorbidities may be challenging, especially in 
heavily pretreated patients whose ART options 
are limited. However, these results also suggest 
that use of PC scores adds information, 
extending beyond a simple pill count or pill 
burden concept.  
Greater prescription and filling complexity is 
known to be associated to lower adherence in 
cardiovascular patients. To date, all studies 
have shown that polypharmacy is robustly 
associated to non-adherence, but no study has 
focused on the HIV population in a large cohort 
in real practice. Non-adherence to ART is 
especially worrying because it is associated to 
decreased viral suppression, allows for viral 
resistance, and increases the risk of 
opportunistic diseases 30–32.  
A systematic review in non-HIV-infected 
patients has shown that although variability was 
seen in the association between complexity and 
adherence, most studies concluded that an 
increased regimen complexity decreases 
medication adherence 33. In our study, the 
overall adherence calculated was high for ART, 
but particularly low for concomitant medication, 
where the main polypharmacy pattern was 
precisely cardiovascular. This suggests 
Ramón Morillo-Verdugo et al., IJOAR, 2019 2:35 
IJOAR: https://escipub.com/international-journal-of-aging-research/                       8
prioritization of drug intake by patients based on 
their beliefs and perceptions about drugs 34. 
The results of the Borrego et al. 35 study 
showed that adherence problems begin at the 
time of prescription, because one third of 
patients will not even collect the prescribed 
medication. 
These results suggest that, in older HIV 
patients, all prescribed drugs should be 
checked at least every six months in individuals 
prescribed more than four drugs, and at least 
once a year in all others. Clinical guidelines 
recommend systematic review of the prescribed 
drug therapy following a sequential and 
structured methodology 6. 
Our results suggest that PC is associated to 
cardiovascular polypharmacy and depression-
anxiety patterns. As expected, the complexity 
index was only related to dosage and 
instructions, since tablets are the most common 
pharmaceutical form currently available. As 
reported, dosing frequency made the largest 
contribution of all components (62%) to the PC 
36. In this line of research, these types of factors 
should thoroughly be reviewed when assessing 
prescriptions and the daily management plan of 
patients, especially for most commonly 
prescribed drugs. 
We propose a redefinition of the concept of 
polypharmacy to include not only the 
quantitative aspect of the number of prescribed 
drugs but, above all, regimen complexity. A cut-
off PC value needs to be proposed to 
determine if a patient meets the polypharmacy 
criterion. 
Limitations 
A common limitation of other published studies 
is that they only include data on officially 
prescribed drugs, thus excluding private health 
system treatments or alternative medicines. 
However, this is not seen as a very significant 
limitation in our study; because of the universal 
coverage of the public health system in Spain, 
only a small number of patients use alternative 
medications. However, the MRCI is an 
imperfect tool and faces tradeoffs between 
sensitivity and specificity, as most clinical 
measures do. Despite a long list of possible 
dose formulations, frequencies, and directions, 
some options are missed, such as once 
monthly, and details such as how to code two 
once-daily drugs that cannot be taken at the 
same time are not considered. There are other 
possibilities to analyze PC, such as the ARCI, 
including many more such details. As the 
average complexity score is not significantly 
different from the MRCI for ART regimens, we 
prefer the MRCI because it has been more 
widely studied in the literature in recent years 
15,37,38. 
It is known that multimorbidity contributes to 
further vulnerability and complexity in clinical 
management in the contemporary ART age. 
Interest in methods to identify individuals at risk 
of multimorbidity is strongest. In geriatric 
medicine, such multisystem vulnerability is 
quantified using the construct of frailty, which is 
a state of increased vulnerability related to 
degradation of homeostatic mechanisms 39. 
The concept of frailty may be useful for 
discriminating whether morbidities themselves 
or the toxicity of prescribed treatments make a 
greater contribution to adverse outcomes 40.  
Because of the changing face of the HIV 
epidemic, healthcare providers will be 
increasingly challenged to effectively manage 
older HIV-infected patients with multimorbidity, 
polypharmacy, and high PC. It is important to 
increase our understanding of polypharmacy in 
the ever increasing number of older HIV-
infected patients in order to be able to develop 
prevention strategies for the problems inherent 
to old age and multiple treatments. 
Future research efforts will focus on risk 
assessment, such as that offered by the PC 
Index, to inform the prioritization of medications 
based on their risks and benefits for each 
patient. In addition, efforts should be made to 
promote public health and multidisciplinary 
initiatives, behavioral changes, and prevention 
aimed at reducing polypharmacy and PC. 
Ramón Morillo-Verdugo et al., IJOAR, 2019 2:35 
IJOAR: https://escipub.com/international-journal-of-aging-research/                      9
The PC index may prove to be useful as a risk 
prediction tool. Additional studies are needed to 
establish its power and to reveal potential 
opportunities for clinical intervention to 
decrease medication complexity as a risk factor 
for nonadherence. Decreasing dosing 
frequencies, simplification of administration 
routes, or counseling on non-prescribed 
supplements and its consequences in use of 
health resources, including hospitalizations, are 
proposed. 
CONCLUSION  
In conclusion, more than a half of older HIV-
positive patients in this study received six or 
more different drugs, with a significant PC. 
Cardiovascular conditions and depression-
anxiety were most common in terms of 
prescriptions and comorbidities. The concept of 
polypharmacy should include not only the 
number of prescribed drugs, but also their 
complexity. 
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